You are here: Industry Insights > CNS

News List

FDA approves Alexion’s Soliris as first treatment for CNS disease NMOSD pharmaceutical-technology
July 01, 2019
Alexion Pharmaceuticals has announced that the US Food and Drug Administration (FDA) has approved Soliris (eculizumab), a first-in-class complement inhibitor, for neuromyelitis optica spectrum disorder (NMOSD) patients who are anti-aquaporin-4 (AQP4) anti
Next-Gen Sequencing of CSF Improves Diagnosis of CNS Infections drugs
June 13, 2019
Next-Gen Sequencing of CSF Improves Diagnosis of CNS Infections.
Regeneron and Alnylam partner on eye and CNS disease therapies pharmaceutical-technology
April 23, 2019
Regeneron and Alnylam partner on eye and CNS disease therapies.
AveXis Data Reinforce Effectiveness of Zolgensma in Treating Spinal Muscular Atrophy (SMA) Type 1 drugs
April 18, 2019
AveXis Data Reinforce Effectiveness of Zolgensma in Treating Spinal Muscular Atrophy (SMA) Type 1.
Regeneron, Alnylam Ink RNAi Alliance contractpharma
April 09, 2019
To discover, develop and commercialize new RNA interference therapeutics for a broad range of diseases
Pair of deals boosts Biogen’s early-stage CNS pipeline pharmaphorum
January 08, 2019
Biogen has signed a brace of collaborations to expand its central nervous system (CNS) pipeline, adding new candidates for Alzheimer’s, multiple sclerosis and other neurological diseases.
Boehringer inks pact with Domain for GPCR neurology drugs fiercebiotech
January 02, 2019
French-Canadian biotech Domain Therapeutics has another big pharma partner, signing a deal with Germany’s Boehringer Ingelheim to develop new drugs for central nervous system (CNS) disorders....
MonoSol Rx Changes Name to Aquestive Therapeutics, Expands CNS Product Portfolio americanpharmaceuticalreview
December 06, 2017
MonoSol Rx announced the change of its corporate name to Aquestive Therapeutics.
Charles River doubles down on CNS research with Brains On-Line buy fiercebiotech
August 10, 2017
Charles River acquires Brains On-Line for €18 million, enhancing its position as a single-source provider for a broad portfolio of CNS discovery services.

Previous page 1 2 3 Next page